Anzeige
Mehr »
Donnerstag, 25.09.2025 - Börsentäglich über 12.000 News
Geheime Börsenchance: Ist das die bedeutendste Kupferentdeckung Kanadas?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40Z30 | ISIN: US29970R3030 | Ticker-Symbol:
NASDAQ
25.09.25 | 16:42
4,380 US-Dollar
+32,73 % +1,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EVAXION A/S ADR Chart 1 Jahr
5-Tage-Chart
EVAXION A/S ADR 5-Tage-Chart

Aktuelle News zur EVAXION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:48Evaxion Out-licenses Vaccine Candidate EVX-B3 To Merck & Co.198KENILWORTH (NJ) (dpa-AFX) - TechBio company Evaxion A/S (EVAX) announced Thursday it has out-licensed its vaccine candidate EVX-B3 to Merck & Co., Inc. or MSD (MRK), as per the option and license...
► Artikel lesen
13:15Evaxion A/S - 6-K, Report of foreign issuer2
13:10Evaxion out-licenses vaccine candidate EVX-B3 to MSD236MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion's cash runway to first half of 2027 MSD will assume full responsibility for the further...
► Artikel lesen
13:06MSD exercises option on Evaxion's vaccine candidate for $7.5 million6
27.08.Evaxion A/S - 6-K, Report of foreign issuer5
EVAXION Aktie jetzt für 0€ handeln
27.08.Evaxion to present at several conferences during the second half of 2025339Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX)...
► Artikel lesen
14.08.Evaxion Biotech ADS GAAP EPS of -$0.022
14.08.Evaxion announces business update and second quarter 2025 financial results416COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update and...
► Artikel lesen
13.08.Insights Ahead: Evaxion Biotech's Quarterly Earnings1
11.08.Evaxion A/S - 6-K, Report of foreign issuer2
11.08.Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025268COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will provide a business update...
► Artikel lesen
25.07.Evaxion A/S - 6-K, Report of foreign issuer3
25.07.Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025424COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will be presenting two-year clinical...
► Artikel lesen
11.07.Evaxion finalizes €3.5 million debt-to-equity deal with EIB3
11.07.Evaxion schließt Debt-to-Equity-Vereinbarung mit EIB über 3,5 Millionen Euro ab 5
11.07.Evaxion A/S - 6-K, Report of foreign issuer4
11.07.Evaxion finalizes agreement with EIB to convert debt into equity380Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion's €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth...
► Artikel lesen
02.07.Evaxion A/S - 6-K, Report of foreign issuer-
01.07.Evaxion Biotech: Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology platform and portfolio401Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commencedThomas Schmidt appointed permanent Chief...
► Artikel lesen
25.06.Evaxion entwickelt neuen Impfstoff gegen Gruppe-A-Streptokokken6
Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1